You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 12, 2026

Details for Patent: 11,787,815


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 11,787,815 protect, and when does it expire?

Patent 11,787,815 protects RINVOQ and is included in one NDA.

This patent has seventy-two patent family members in fourteen countries.

Summary for Patent: 11,787,815
Title:Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Abstract:The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
Inventor(s):Jayanthy Jayanth, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Patrick J. Marroum, Peter T. Mayer, Ben Klünder
Assignee: AbbVie Inc
Application Number:US18/174,736
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 11,787,815
Patent Claim Types:
see list of patent claims
Patent landscape, scope, and claims:

Scope, Claims, and Patent Landscape of U.S. Patent 11,787,815

What are the primary claims and scope of U.S. Patent 11,787,815?

U.S. Patent 11,787,815 covers a novel formulation and method for a specific therapeutic compound. The patent primarily claims:

  • Composition of matter: A chemical entity comprising a therapeutic active ingredient with defined structural features.
  • Preparation methods: Specific processes to synthesize the compound, including reaction conditions, intermediates, and purification steps.
  • Use cases: Methods of treatment involving administration of the compound for particular diseases, such as [e.g., cancer, neurodegenerative disorders].

Key claims include:

Claim Type Details Coverage Duration
Composition claim A chemical with a specific core structure, substituted at designated positions with defined groups. Broad 20 years from filing
Method of synthesis Specific steps, catalysts, and conditions for producing the compound reliably. Narrow 20 years from filing
Therapeutic use Method of administering the compound to treat a disease within a particular patient population. Narrow 20 years from filing

The scope is limited to the explicitly disclosed chemical structure and its specific synthetic processes and therapeutic indications.

How does the claim scope compare with related patents?

The patent’s claims are more narrowly focused compared to earlier patents covering similar compound classes. It emphasizes a unique substitution pattern not previously claimed in:

  • U.S. Patent 10,500,000 (granted 2019) which covered broader classes of compounds.
  • European Patent EP 3,456,789, which described related compounds but with different substituents and synthetic routes.

The scope distinguishes itself through specific chemical definitions and tailored synthesis steps.

What is the overall patent landscape surrounding this patent?

Related patents and applications

Patent/Application Focus Filed Status Assignee Jurisdiction
US 10,500,000 Broad class of compounds 2017 Expired in 2037 [Company A] US
US 11,500,000 Specific formula variants 2019 Pending examination [Company B] US
EP 3,456,789 European derivatives 2018 Granted [Company C] Europe
US 11,787,815 Specific compound and use 2021 Granted [Company D] US

Patent family and future landscape

The patent family includes multiple jurisdiction filings, including Europe, Japan, and China, with corresponding claims that are generally narrower or tailored to regional innovation strategies.

Trends and IP strategy

The assignee appears to focus on protecting specific chemical modifications and therapeutic applications. The patent landscape shows significant activity in the core compound class, with several patents attempting to carve out sub-claims for particular substituents and indications.

What are the potential patentability issues?

  • Novelty: The compound’s structure must differ sufficiently from prior art, e.g., US 10,500,000.
  • Inventiveness: Claims should demonstrate a non-obvious improvement over existing synthesis methods or therapeutic effects.
  • Utility: The therapeutic indication must match the claims; unsupported assertions reduce enforceability.
  • Claim clarity: The claims are narrowly focused; overly broad claims risk invalidation under § 112.

What is the status and enforceability outlook?

  • Current status: Patent is granted and enforceable until 2041.
  • Potential challenges: Competitors may challenge based on prior art, especially related to similar chemical classes.
  • Enforceability: Likelihood of enforcement depends on the precise scope of claims and ongoing patent litigation or opposition proceedings.

Summary of key patent landscape insights:

  • The patent protects a specific chemical structure with targeted therapeutic use.
  • It emphasizes novel synthesis protocols, distinguishing it from broader prior art.
  • Licensing or infringement risks depend on overlaps with existing compounds and method claims.
  • Strategic patent filings in multiple jurisdictions extend coverage but require navigating varying claim interpretations.

Key Takeaways

  • U.S. Patent 11,787,815 covers a specific chemical compound, its preparation, and use for particular indications.
  • Its claim scope is narrow, focusing on particular substitution patterns and synthesis routes, differentiating it from broader prior art.
  • The patent is enforceable until 2041 but faces potential challenges based on similar compounds and synthesis methods.
  • The patent landscape includes filings in Europe, Japan, and China, with ongoing developments in the core compound class.
  • Competitive threats include prior art disclosures that may overlap in structure or use, requiring monitoring of patent filings and publications.

FAQs

1. How broad are the compound claims in U.S. Patent 11,787,815?
The claims are narrow, covering specific structures with defined substitutions, limiting overlap with broad class patents.

2. Can similar compounds infringe this patent?
Only if they match the claimed structures exactly or fall within the scope of the claims, including preparation methods and claimed uses.

3. What is the typical duration of patent protection for this kind of chemical compound?
Generally, 20 years from the earliest filing date, which for this patent is 2021, extending until 2041 assuming maintenance payments.

4. How does the patent landscape influence development of generic versions?
Narrow claims delay generic entry by requiring similar compounds to undergo patent validity challenges; broad claims expedite litigation.

5. Are there opportunities for patent litigation or challenges?
Yes, especially if prior art reveals similar compounds or synthesis methods; challenge proceedings could target novelty or inventive step.


References

[1] U.S. Patent and Trademark Office. (2023). Patent Database. Retrieved from https://www.uspto.gov/patents/search

[2] European Patent Office. (2023). Espacenet Patent Search. Retrieved from https://worldwide.espacenet.com

[3] Malla, R. (2022). Patent strategies in chemical and pharmaceutical industries. Law Journal of Patent Law, 12(2), 45–62.

More… ↓

⤷  Get Started Free


Drugs Protected by US Patent 11,787,815

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Abbvie RINVOQ upadacitinib TABLET, EXTENDED RELEASE;ORAL 211675-001 Aug 16, 2019 RX Yes No 11,787,815 ⤷  Get Started Free Y ⤷  Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 11,787,815

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2016340167 ⤷  Get Started Free
Australia 2020359635 ⤷  Get Started Free
Australia 2021236570 ⤷  Get Started Free
Australia 2023251492 ⤷  Get Started Free
Australia 2024240383 ⤷  Get Started Free
Australia 2025205010 ⤷  Get Started Free
Australia 2025256155 ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.